Clinical Trials Arena on MSN
Zenas’ MS drug reduces new brain lesion formation by 95% in Phase II trial
If approved, Zenas will enter the RMS market, which is currently dominated by anti-CD20 antibodies like Roche’s Ocrevus.
A retrospective chart review of pediatric patients with MS at a tertiary treatment center showed how the center’s first ...
Bazedoxifene, a drug that alters the activity of the sex hormone estrogen, failed to promote myelin repair in women with MS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results